Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.59 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.54 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 4/20 | 0.52 |
| ▸ | CA2 | P00918 | 4/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33494 | 0.94 | LOXL2 (0.66) | LOXL2CYP4A11CYP4F2CA1CA2 | |
| Bromide SCHEMBL4809006 | 0.92 | LOXL2 (0.63) | LOXL2CYP4A11CYP4F2CA1CA2 | |
| SCHEMBL4050879 | 0.92 | LOXL2 (0.63) | LOXL2CYP4A11CYP4F2CA1CA2 | |
| SCHEMBL7021444 | 0.89 | LOXL2 (0.59) | LOXL2CYP4A11CYP4F2CA1CA2 | |
| Acetonitrile SCHEMBL23628987 | 0.86 | LOXL2 (0.56) | LOXL2CYP4A11CYP4F2CA1CA2 | |
| SCHEMBL2839451 | 0.86 | CA1 (0.56) | LOXL2CYP4A11CYP4F2CA1CA2 | |
| 4-Methylbenzoic Acid Methyl Ester SCHEMBL7376893 | 0.84 | TDP1 (0.67) | LOXL2CYP4A11CYP4F2CA1CA2 | |
| SCHEMBL187134 | 0.84 | CES2 (0.61) | MAPTKMT2ATSHRALDH1A1HPGD | |
| SCHEMBL2337244 | 0.84 | CA1 (0.70) | LOXL2CYP4A11CA1CA2CA12 | |
| SCHEMBL9541276 | 0.84 | CES2 (0.61) | MAPTKMT2ATSHRALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112097-A1 | Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-05-12 | — | — | US | disclosed |
| EP-0888389-B1 | PHOTOACTIVATABLE CHAIN TRANSFER AGENTS | SURMODICS INC (US) | 2004-08-04 | — | — | EP | disclosed |
| EP-0733633-B1 | Heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-05-28 | — | — | EP | disclosed |
| EP-0888389-A4 | PHOTOACTIVATABLE CHAIN TRANSFER AGENTS | SURMODICS INC (US) | 2001-03-14 | — | — | EP | disclosed |
| US-5942555-A | Photoactivatable chain transfer agents and semi-telechelic photoactivatable polymers prepared therefrom | SURMODICS, INC. (US) | 1999-08-24 | — | — | US | disclosed |
| EP-0888389-A1 | PHOTOACTIVATABLE CHAIN TRANSFER AGENTS | SurModics, Inc. (US) | 1999-01-07 | — | — | EP | disclosed |
| US-5753664-A | ANTITUMOR AGENTS, PYRIMIDONES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-05-19 | — | — | US | disclosed |
| WO-1997034935-A1 | PHOTOACTIVATABLE CHAIN TRANSFER AGENTS | BSI CORPORATION (US) | 1997-09-25 | — | — | WO | disclosed |
| EP-0733633-A1 | Heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-09-25 | — | — | EP | disclosed |
| US-4040923-A | COATINGS, MOLDINGS | EASTMAN KODAK COMPANY (US) | 1977-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112097-A1 | Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | GIPR, PGC, DDC | LOXL2 2751/4885CYP4A11 261/4885CYP4F2 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.